Author

M. A. Wood

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. Nellore· 2 shared R. F. Thompson· 2 shared A. J. Struck· 1 shared A. Margolin· 1 shared A. Nguyen· 1 shared B. R. Weeder· 1 shared J. K. David· 1 shared K. Ellrott· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Nellore

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival

M. A. Wood, B. R. Weeder, J. K. David, A. Nellore, R. F. Thompson

This study evaluates tumor mutational burden (TMB) and related metrics as predictors of immunotherapy response and survival, finding limited predictive value in some cancers and instability in its use.

bioRxiv · Jan 28, 2020Cancer Biology

Population-level distribution and putative immunogenicity of cancer neoepitopes

M. A. Wood, M. Paralkar, M. P. Paralkar, A. Nguyen, A. J. Struck, K. Ellrott, A. Margolin, A. Nellore, R. F. Thompson

The paper introduces four metrics to prioritize neoepitopes based on peptide novelty and evaluates their immunogenicity using TCGA and melanoma patient data.

BMC Cancer · Apr 13, 2018Peer-reviewedCancer Biology